Nanobiotix S.A. (NBTX)

5.83 +0.02 (+0.34%) 市場開市。 截至 09:32AM EDT。

Nanobiotix S.A.

60 rue de Wattignies
Paris 75012
France
33 1 40 26 04 70
https://www.nanobiotix.com

版塊: Healthcare
行業: Biotechnology
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Laurent Levy Ph.D.	Co-Founder, President of the Executive Board & CEO	764.29k	無	1973
Mr. Bart Van Rhijn	CFO & Member of Executive Board	672.88k	無	1973
Ms. Anne-Juliette Hermant M.A.	Chief People Officer & Member of Executive Board	379.97k	無	1974
Dr. Louis Kayitalire M.D.	Chief Medical Officer	536.17k	無	1958
Mr. Earl J. Bergey Ph.d.	Co-Founder	無	無	1955
Mr. Alain Dostie	Chief Operating Officer	無	無	無
Mr. Craig West CFA	Senior Vice President of Investor Relations	無	無	無
Mr. Brandon Owens	VP of Strategic Marketing & Corporate Communication	無	無	無
Mr. Patrick Tricoli M.B.A., Pharm.D.	Global Head of Business Development	無	無	無
Ms. Margaret Galluzzi	VP & Global Head of Clinical Operations	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

公司管治

截至 2024年4月29日 止，Nanobiotix S.A. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：9；董事會：7；股東權利：7；現金賠償：10。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。